CAR-T Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about CAR-T clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Leukemia RelapseLymphoma Diffuse Large B-cellLeukemia and Lymphoma+1 more
AvenCell Therapeutics, Inc.178 enrolled6 locationsNCT07284433
Recruiting
Phase 2

DALY II Japan/MB-CART2019.1 for DLBCL

DLBCL - Diffuse Large B Cell LymphomaCAR-T Cell Therapy
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879
Recruiting
Early Phase 1

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Small Cell Lung Cancer ( SCLC )CAR-T Cell Therapy
TCRCure Biopharma Ltd.24 enrolled1 locationNCT07246304
Recruiting

Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy

Lymphoma Receiving CAR-T Therapy
Memorial Sloan Kettering Cancer Center120 enrolled1 locationNCT04107285
Recruiting
Phase 1

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CAR-T Cell TherapyAcute Myeloid Leukemia (AML)
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT07198867
Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

SepsisLiver Transplant; ComplicationsPancreatitis+15 more
CytoSorbents, Inc3,000 enrolled28 locationsNCT05146336
Recruiting

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

Acute Lymphoblastic LeukemiaMultiple MyelomaHematologic Malignancy+2 more
Assistance Publique - Hôpitaux de Paris60 enrolled1 locationNCT06350994
Recruiting
Early Phase 1

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)CAR-T
Zhimin Zhai9 enrolled1 locationNCT06642025
Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LymphomaLeukemiaCAR-T Cell Therapy+3 more
University of Arizona100 enrolled1 locationNCT06643221
Recruiting
Phase 1

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Pancreas CancerSolid Tumor, AdultCAR-T Cell Therapy+1 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT05779917
Recruiting
Phase 1

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Lung CancerCancerImmunotherapy+1 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled2 locationsNCT03198052
Recruiting
Phase 1

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Liver CancerLung CancerPancreas Cancer+3 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT06196294
Recruiting
Phase 2

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Very High Risk Acute Lymphoblastic LeukemiaCD19 CAR-T Therapy
Seoul National University Hospital50 enrolled1 locationNCT06247501